Samsa, I am myself hoping to be wrong, but I thought (as you) Rexista wasn't priced in before the AdCOmm, and we went from 2.80 to 1.15. So I do agree a total failure is priced in at the moment, but let a negative outcome arrive and company hasn't already resolved the cash/partnership issue (or announced something new), then the market will discount a big dilution.
So I have my stomach upsidedown when I think Odidi could be so stubborn to go alone/naked in front of the FDA again.
Market Data 
Markets 
AI
